BR0313664A - Compostos inibidores nucleosìdeo fosforilase e nucleosidases, suas composições e seus usos - Google Patents

Compostos inibidores nucleosìdeo fosforilase e nucleosidases, suas composições e seus usos

Info

Publication number
BR0313664A
BR0313664A BR0313664-7A BR0313664A BR0313664A BR 0313664 A BR0313664 A BR 0313664A BR 0313664 A BR0313664 A BR 0313664A BR 0313664 A BR0313664 A BR 0313664A
Authority
BR
Brazil
Prior art keywords
compounds
compositions
inhibitor compounds
nucleoside phosphorylase
methylthioadenosine
Prior art date
Application number
BR0313664-7A
Other languages
English (en)
Other versions
BRPI0313664B1 (pt
BRPI0313664B8 (pt
Inventor
Gary Brian Evans
Richard Hubert Furneaux
Dirk Henning Lenz
Vern L Schramm
Peter Charles Tyler
Olga Vladmirovna Zubkova
Original Assignee
Einstein Coll Med
Ind Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Einstein Coll Med, Ind Res Ltd filed Critical Einstein Coll Med
Publication of BR0313664A publication Critical patent/BR0313664A/pt
Publication of BRPI0313664B1 publication Critical patent/BRPI0313664B1/pt
Publication of BRPI0313664B8 publication Critical patent/BRPI0313664B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Seal Device For Vehicle (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"COMPOSTOS INIBIDORES DE NUCLEOSìDEO FOSFORILASE E NUCLEOSIDASES, SUAS COMPOSIçõES E SEUS USOS". A presente invenção se refere a compostos de formula geral (I) os quais são inibidores de nucleosídeo fosforilase de purina (PNP), fosforibosiltransferase de purina (PPRT), fosforilase de 5<39>-metiltioadenosina (MTAP), nucleosidade de 5<39>-metiltioadenosina (MTAN) e/ou hidrolase de nucleosídeo (NH) . A invenção também se refere ao uso destes compostos no tratamento de doenças e infecções incluindo câncer, infecções bacterianas, infecções por protozoários e doença mediada da célula-T e composições farmacêuticas contendo estes compostos.
BRPI0313664A 2002-08-21 2003-08-21 compostos inibidores de nucleosídeo fosforilase e nucleosidases, suas composições e seus usos BRPI0313664B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ52091902 2002-08-21
NZ520919 2002-08-21
PCT/NZ2003/000186 WO2004018496A1 (en) 2002-08-21 2003-08-21 Inhibitors of nucleoside phosphorylases and nucleosidases

Publications (3)

Publication Number Publication Date
BR0313664A true BR0313664A (pt) 2005-07-12
BRPI0313664B1 BRPI0313664B1 (pt) 2021-03-23
BRPI0313664B8 BRPI0313664B8 (pt) 2021-05-25

Family

ID=31944950

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0313664A BRPI0313664B8 (pt) 2002-08-21 2003-08-21 compostos inibidores de nucleosídeo fosforilase e nucleosidases, suas composições e seus usos

Country Status (18)

Country Link
US (2) US7553839B2 (pt)
EP (1) EP1539783B1 (pt)
JP (1) JP4682314B2 (pt)
KR (1) KR101081226B1 (pt)
CN (1) CN100379750C (pt)
AT (1) ATE505474T1 (pt)
AU (1) AU2003258911B2 (pt)
BR (1) BRPI0313664B8 (pt)
CA (1) CA2496698C (pt)
CY (1) CY1111700T1 (pt)
DE (1) DE60336734D1 (pt)
DK (1) DK1539783T3 (pt)
ES (1) ES2363766T3 (pt)
HK (1) HK1085219A1 (pt)
PT (1) PT1539783E (pt)
RU (1) RU2330042C2 (pt)
SI (1) SI1539783T1 (pt)
WO (1) WO2004018496A1 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985848A (en) * 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
EP1165564B1 (en) * 1999-04-08 2009-03-11 Industrial Research Limited Process for preparing inhibitors of nucleoside metabolism
US7553839B2 (en) 2002-08-21 2009-06-30 Industrial Research Limited 5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
NZ523970A (en) * 2003-02-04 2005-02-25 Ind Res Ltd Process for preparing inhibitors of nucleoside phoshorylases and nucleosidases
US7557113B2 (en) 2003-08-26 2009-07-07 Teijin Pharma Limited Substituted pyrrolo[3,2-d]pyrimidine derivatives
AR045507A1 (es) * 2003-08-26 2005-11-02 Teijin Pharma Ltd Derivados de pirrolo [3,2-d] pirimidina
NZ533360A (en) * 2004-06-04 2007-02-23 Ind Res Ltd Improved method for preparing 3-hydroxy-4-hydroxymethyl-pyrrolidine compounds
WO2006014913A2 (en) * 2004-07-27 2006-02-09 Biocryst Pharmaceuticals, Inc. Inhibitors of 5'-methylthioadenosine phosphorylase and 5'methylthioadenosine/s-adenosylhomocysteine nucleosidase
NZ540160A (en) * 2005-05-20 2008-03-28 Einstein Coll Med Inhibitors of nucleoside phosphorylases
EP1924684A4 (en) * 2005-07-27 2009-02-11 Einstein Coll Med STRUCTURE OF TRANSITION STATUS OF 5'-METHYLTHIOADENOSINE / S-ADENOSYLHOMOCYSTEINE NUCLEOSIDASES
NZ544187A (en) * 2005-12-15 2008-07-31 Ind Res Ltd Deazapurine analogs of 1'-aza-l-nucleosides
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
US8394950B2 (en) * 2006-02-22 2013-03-12 Industrial Research Limited Analogues of coformycin and their use for treating protozoan parasite infections
AU2007218334A1 (en) * 2006-02-24 2007-08-30 Albert Einstein College Of Medicine Of Yeshiva University Methods of treating diseases using inhibitors of nucleoside phosphorylases and nucleosidases
US8916571B2 (en) 2006-02-24 2014-12-23 Albert Einstein College Of Medicine Of Yeshiva University Methods of treating cancer using inhibitors of 5′-methylthioadenosine phosphorylase
AU2006200809B2 (en) * 2006-02-24 2013-11-07 Albert Einstein College Of Medicine Of Yeshiva University Methods of treating cancer
CN101094080B (zh) * 2006-06-22 2012-06-20 华为技术有限公司 一种即按即通系统中的计费方法
ES2362805T3 (es) 2006-09-07 2011-07-13 Industrial Research Limited Inhibidores aminoacíclicos de nucleósido fosforilasas e hidrolasas.
EP2049543B1 (en) 2006-09-07 2014-11-05 Callaghan Innovation Research Limited Acyclic amine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase
ES2385759T3 (es) * 2006-12-22 2012-07-31 Industrial Research Limited Análogos azetidina de inhibidores de nucleosidasa y fosforilasa
WO2009082247A1 (en) * 2007-12-21 2009-07-02 Industrial Research Limited Process for preparing immucillins having a methylene link
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
EP2348854A4 (en) 2008-09-22 2012-03-14 Einstein Coll Med METHOD AND COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS BY INHIBITING THE "QUORUM SENSING
US8501753B2 (en) * 2009-03-24 2013-08-06 Biocryst Pharmaceuticals, Inc. Useful pharmaceutical salts of 7-[(3R, 4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3, 5-dihydro-pyrrolo [3, 2-D] pyrimidin-4-one
JP5861243B2 (ja) 2009-07-17 2016-02-16 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ ５’−メチルチオアデノシンホスホリラーゼ及びヌクレオシダーゼの３−ヒドロキシピロリジン阻害剤
WO2012074912A1 (en) * 2010-11-29 2012-06-07 Albert Einstein College Of Medicine Of Yeshiva University Methods, assays and compounds for treating bacterial infections by inhibiting methylthioinosine phosphorylase
WO2012122532A2 (en) * 2011-03-09 2012-09-13 Biocryst Pharmaceuticals, Inc. Compositions and methods for treatment of hyperuricemia
WO2013014052A1 (en) 2011-07-22 2013-01-31 Glaxosmithkline Llc Composition
JP6063571B2 (ja) 2012-08-07 2017-01-18 アルバート アインシュタイン カレッジ オブ メディシン，インコーポレイティド ヘリコバクター・ピロリ感染の治療
EP2888264B1 (en) 2012-08-24 2017-09-27 Glaxosmithkline LLC Pyrazolopyrimidine compounds
JP6587252B2 (ja) * 2012-11-12 2019-10-09 ヴィクトリア リンク リミテッドＶｉｃｔｏｒｉａ Ｌｉｎｋ Ｌｉｍｉｔｅｄ （３ｒ，４ｓ）−ｌ−（（４−アミノ−５ｈ−ピロロ［３，２−ｄ］ピリミジン−７−イル）メチル）−４−（メチルチオメチル）ピロリジン−３−オール（ｍｔｄｉａ）の塩及び多形形態
BR112015011439A2 (pt) 2012-11-20 2017-07-11 Glaxosmithkline Llc composto, composição farmacêutica, composição de vacina, e, uso de um composto
HUE13857477T2 (hu) 2012-11-20 2018-05-28 Glaxosmithkline Llc Új vegyületek
ES2632448T3 (es) 2012-11-20 2017-09-13 Glaxosmithkline Llc Nuevos compuestos
EP3010340A4 (en) 2013-06-22 2017-08-02 Nitor Therapeutics Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
RU2663803C2 (ru) 2014-02-12 2018-08-09 Альберт Эйнштейн Колледж Оф Медсин, Инк. Лечение инфекций h. pylori с применением ингибиторов mtan
EP2913333A1 (en) * 2014-02-27 2015-09-02 Laboratoire Biodim 3H-thieno[3,4]pyrimidin-4-one and pyrrolopyrimidone as gram-positive antibacterial agents
CN108794628A (zh) * 2018-05-28 2018-11-13 广东工业大学 一种抗幽门螺杆菌的卵黄抗体制备方法及应用
GB202110403D0 (en) 2021-07-20 2021-09-01 Laevoroc Immunology Ulodesine Salt

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2866478B2 (ja) * 1989-10-31 1999-03-08 バイオクリスト・ファーマシューティカルズ・インコーポレイテッド プリンヌクレオシドホスホリラーゼの阻害剤
JPH07242668A (ja) * 1994-03-08 1995-09-19 Nippon Kayaku Co Ltd 新規なアゼチジン誘導体
JPH10507171A (ja) * 1994-10-05 1998-07-14 カイロサイエンス・リミテッド Ｐｎｐインヒビターとしてのプリンおよびグアニン化合物
WO1996030346A1 (fr) * 1995-03-29 1996-10-03 Taiho Pharmaceutical Co., Ltd. Derives d'uracile, agents de potentialisation d'effet antitumoral et agent antitumoral renfermant ces derives
WO1997031008A1 (en) 1996-02-23 1997-08-28 Industrial Research Limited Enzyme detection/assay method and substrates
US5985848A (en) 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
EP1165564B1 (en) 1999-04-08 2009-03-11 Industrial Research Limited Process for preparing inhibitors of nucleoside metabolism
US6448799B1 (en) * 1999-09-30 2002-09-10 Hitachi Electronics Engineering Co., Ltd. Timing adjustment method and apparatus for semiconductor IC tester
JP4110347B2 (ja) 1999-11-05 2008-07-02 大鵬薬品工業株式会社 抗ｈｉｖ剤
AU2001284564A1 (en) 2000-08-29 2002-03-13 Albert Einstein College Of Medicine Of Yeshiva University Nucleoside metabolism inhibitors
US6458799B1 (en) 2000-08-31 2002-10-01 Biocryst Pharmaceuticals, Inc. Deazaguanine analog, preparation thereof and use thereof
US7098334B2 (en) 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
US7553839B2 (en) 2002-08-21 2009-06-30 Industrial Research Limited 5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
NZ523970A (en) 2003-02-04 2005-02-25 Ind Res Ltd Process for preparing inhibitors of nucleoside phoshorylases and nucleosidases
NZ533360A (en) 2004-06-04 2007-02-23 Ind Res Ltd Improved method for preparing 3-hydroxy-4-hydroxymethyl-pyrrolidine compounds
WO2006014913A2 (en) 2004-07-27 2006-02-09 Biocryst Pharmaceuticals, Inc. Inhibitors of 5'-methylthioadenosine phosphorylase and 5'methylthioadenosine/s-adenosylhomocysteine nucleosidase
NZ540160A (en) 2005-05-20 2008-03-28 Einstein Coll Med Inhibitors of nucleoside phosphorylases
EP1924684A4 (en) 2005-07-27 2009-02-11 Einstein Coll Med STRUCTURE OF TRANSITION STATUS OF 5'-METHYLTHIOADENOSINE / S-ADENOSYLHOMOCYSTEINE NUCLEOSIDASES
NZ544187A (en) * 2005-12-15 2008-07-31 Ind Res Ltd Deazapurine analogs of 1'-aza-l-nucleosides
AU2007218334A1 (en) 2006-02-24 2007-08-30 Albert Einstein College Of Medicine Of Yeshiva University Methods of treating diseases using inhibitors of nucleoside phosphorylases and nucleosidases
US8916571B2 (en) * 2006-02-24 2014-12-23 Albert Einstein College Of Medicine Of Yeshiva University Methods of treating cancer using inhibitors of 5′-methylthioadenosine phosphorylase
ES2362805T3 (es) 2006-09-07 2011-07-13 Industrial Research Limited Inhibidores aminoacíclicos de nucleósido fosforilasas e hidrolasas.
EP2049543B1 (en) * 2006-09-07 2014-11-05 Callaghan Innovation Research Limited Acyclic amine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase
US20100062995A1 (en) * 2006-09-26 2010-03-11 Schramm Vern L Transition state structure of human 5'methylthioadenosine phosphorylase
ES2385759T3 (es) * 2006-12-22 2012-07-31 Industrial Research Limited Análogos azetidina de inhibidores de nucleosidasa y fosforilasa
WO2009082247A1 (en) 2007-12-21 2009-07-02 Industrial Research Limited Process for preparing immucillins having a methylene link
EP2348854A4 (en) 2008-09-22 2012-03-14 Einstein Coll Med METHOD AND COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS BY INHIBITING THE "QUORUM SENSING
JP5861243B2 (ja) 2009-07-17 2016-02-16 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ ５’−メチルチオアデノシンホスホリラーゼ及びヌクレオシダーゼの３−ヒドロキシピロリジン阻害剤

Also Published As

Publication number Publication date
US8173662B2 (en) 2012-05-08
RU2005107714A (ru) 2006-01-20
AU2003258911A1 (en) 2004-03-11
EP1539783A1 (en) 2005-06-15
US7553839B2 (en) 2009-06-30
BRPI0313664B1 (pt) 2021-03-23
KR20050093756A (ko) 2005-09-23
PT1539783E (pt) 2011-06-01
CA2496698A1 (en) 2004-03-04
AU2003258911B2 (en) 2009-11-19
US20060160765A1 (en) 2006-07-20
EP1539783A4 (en) 2010-05-19
US20090239885A1 (en) 2009-09-24
SI1539783T1 (sl) 2011-08-31
BRPI0313664B8 (pt) 2021-05-25
WO2004018496A1 (en) 2004-03-04
JP2006501239A (ja) 2006-01-12
RU2330042C2 (ru) 2008-07-27
KR101081226B1 (ko) 2011-11-07
ATE505474T1 (de) 2011-04-15
CN1692120A (zh) 2005-11-02
CY1111700T1 (el) 2015-10-07
CA2496698C (en) 2012-01-24
CN100379750C (zh) 2008-04-09
DE60336734D1 (de) 2011-05-26
EP1539783B1 (en) 2011-04-13
HK1085219A1 (en) 2006-08-18
JP4682314B2 (ja) 2011-05-11
DK1539783T3 (da) 2011-06-20
ES2363766T3 (es) 2011-08-16

Similar Documents

Publication Publication Date Title
BR0313664A (pt) Compostos inibidores nucleosìdeo fosforilase e nucleosidases, suas composições e seus usos
ATE552259T1 (de) Inhibitoren von nukleosidphosphorylasen und - nukleosidasen
ATE502038T1 (de) Azyklische amininhibitoren von nukleosidphosphorylasen und hydrolasen
WO2006014913A3 (en) Inhibitors of 5&#39;-methylthioadenosine phosphorylase and 5&#39;methylthioadenosine/s-adenosylhomocysteine nucleosidase
CY1106933T1 (el) Ενωσεις πυριμιδινης
ES2195785A1 (es) Nuevos derivados de piridazin-3(2h)-ona.
MXPA04003668A (es) Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos.
ME00275B (me) ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
HRP20050417B1 (hr) Antiviralni derivati nukleozida
ATE245648T1 (de) 1h-pyrazolo(3,4-d)pyrimidine-4,6-dione als inhibitoren für die vermehrung von t-zellen
DK1537116T3 (da) Pyrazolopyrimidiner egnede til behandling af cancersygdomme
MEP36908A (en) omega-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
BR9911612A (pt) Composições de pirrolo[2,3d]pirimidina e seus usos
NO20053144L (no) Chk-, Pdk- og Akt-inhibitorpyrimidiner, deres fremstilling og anvendelse som famasoytiske midler.
HUP0004211A2 (hu) PDE-5 inhibitorok alkalmazása tüdõ magas vérnyomás kezelésére szolgáló gyógyszerkészítmények elõállítására
WO2002079193A8 (en) Inhibitors of cyclin dependent kinases as anti-cancer agent
HRP20050184B1 (hr) Uporaba alkilfosfoholina u kombinaciji s protutumorskim lijekovima
CY1110666T1 (el) Πυραζολοπυριμιδινες καταλληλες για θεραπεια καρκινικων νοσων
NO20053903L (no) Nukleotidlipidesterderivater.
WO2003017939A3 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
AU2003215680A1 (en) New-4-(pyrrolopyrimidin-6-yl)benzenesulphonamide derivatives
WO2002092062A3 (en) Combination of vitamin d analogue and pyrimidine nucleoside analogue
TR200103398T2 (tr) íkameli fenilsikloheksankarboksamitler ve bunlarìn adenozin alìnìmìnìn inhibit”rleri olarak kullanìmì
HUP0301915A2 (hu) Sildenafil és egyéb PDE5 inhibitor hatású vegyületek alkalmazása korai magömlés kezelésére szolgáló gyógyszerkészítmény elżállítására

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNI

Free format text: SEDE DO SEGUNDO TITULAR ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070123928/RJ DE 04/09/2007.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNI

B25A Requested transfer of rights approved

Owner name: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNI

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 11.2 NA RPI NO 2476 DE 19/06/2018 POR TER SIDO INDEVIDA.

B25A Requested transfer of rights approved

Owner name: VICTORIA LINK LIMITED (NZ) ; ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US)

Owner name: VICTORIA LINK LIMITED (NZ) ; ALBERT EINSTEIN COLLE

B25D Requested change of name of applicant approved

Owner name: VICTORIA LINK LIMITED (NZ) ; ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US)

Owner name: VICTORIA LINK LIMITED (NZ) ; ALBERT EINSTEIN COLLE

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/08/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF